The present invention relates to compounds of general formula (I): wherein: R1 represents: halogen, CN or NO2； R2 represents: hydrogen or halogen； n represents: 1 or 2； R3 represents: phenyl substituted by one or more halogens or C1-C6 alkyls； or a cyclohexyl； as well as the therapeutically-acceptable salts or solvates thereof. These compounds are useful as protease-activated receptor-1 (PAR-1) antagonists, particularly in the treatment of thrombosis.
